Neurizon Raises A$4.3 Million, Targets Further A$2 Million as It Clears Convertible Notes
NUZ: $0.065 -24.42% · MC: $48M
Neurizon Therapeutics has secured firm commitments for a A$4.3 million share placement and is targeting a further A$2 million through a shareholder plan, replacing a potential drawdown under its convertible-note facility. It has redeemed all remaining notes, leaving none on issue and removing potential conversion dilution; the company says it remains funded through the HEALEY trial’s expected topline readout. The new funding follows its October quarterly update, which reported A$11 million in cash and said it was fully funded through the readout.

Comments